Q3 2023 Catalent Inc Earnings Call
Significantly short of our expectations and our February forecast.
We accept to be sponsor ability for disappointing to you.
You should also not be taking get.
This longer to finalize our financial reports, even though we and our third party advisor. So it would be using this time to engage in a deep and thorough review of our accounts and our financial reporting processes.
Because that work is ongoing.
A few specific details I can provide you today regarding our financial performance, but I will share what the news I can give you a sense of how we got to where we are and explain our path forward.
As we indicated in our April 14 inmate eight business updates a combination of operational and productivity issues as well as our forecasting challenges ever led us to significantly reduce both our fiscal 2015 net revenue and adjusted EBITDA guidance.
We're not reducing our fiscal 2000, <unk> net revenue guidance to a range from four to 25 to four point to $35 billion.
And we are reducing our adjusted EBITDA guidance to a range from seven to $5 million to $775 million.
It is important to note that this range is reflected that are significant that gene therapy product.
Gain to be treated in the third quarter as a commercial product for accounting policies and.
While our evaluation remains ongoing we anticipate continuing to record revenue for these product entirely on a percentage of completion basis. So.
I understand how these appointing our further revised guidance is for all of you.
I share your disappointment.
God Atlanta has established itself as a global leader in <unk> manufacturing and delivery.
And produce exceptional results between vessels in patients over the last.
Several years.
But as your CEO .
I'm responsible not only for the successor, but also for our good performance this quarter and this year.
I am committed to putting calculate their contractor so should a stronger fiscal 'twenty four and that we return to building long term shareholder value.
To that end on this call I will explain to you the operational challenges and other issues that contributed to our expected Q3 results antibodies guidance.
This will include the walking us through the reasons why we believe that the operational challenges behind this quarter's disappointing performance and revised outlook are temporary and addressable.
I'll then outline the actions we have taken to increase the rigor and discipline.
In our forecasting.
I'll also briefly discuss the factors.
Including an accounting adjustments at Bloomington.
That are expected to lead to the filing of an amended 10-K for fiscal 'twenty two.
And they have delayed the filing of our third quarter fiscal 'twenty three 10-Q.
Finally, and most importantly, I'll remind you our positive long term vision.
Our vision that wireless fully reflective of our short term challenges that continues through two covenants long term opportunities for four months and growth with the confidence and optimism.
Catherine there remains a great company and we are committed to remaining our customers number one CMO partner in helping pharmaceutical biotech and delta innovators to develop deliver and supply products that improve people's lives.
Before I do that.
Let me assure you regarding some concerns we've heard from investors over the last few weeks.
The disappointing third quarter results that we expect to report we're not you.
Q2, any GMP compliance issues or the loss of any customer or cost of the order.
Our customer supply situations remain healthy and we believe we can sufficiently service that demand.
We continue to be an essential part of any individual stock manufacturing and delivery solutions that positively impact patients.
We continue to win significant new business.
Recent notable examples of these include a new expansion of our long term supply agreements with both Novo Nordisk and Samsung biopsies.
With that.
Let's review the operational challenges that materially and have divested impacted the EBITDA in the third quarter and our full year guidance.
As we first communicated on April 14th.
During the third quarter, we began to present these identified productivity challenges and near term expected cost.
Our drug product manufacturing facility is located in Bloomington and Brussels.
These issues drove our EBITDA reduction in our.
<unk> guidance to be greater than our revenue reduction due to the following dynamics.
First even where revenues were delayed or missed the majority of the LIBOR and overnight the costs that remained.
Second our plans to reduce our cost base, we are delayed in order to implement the corrective and preventive actions following the regulatory inspections earlier in the fiscal year in our biologics segment.
Finally balance sheet adjustment in inventory reserves for soon to expire and vital manufacturing components and raw materials procured during the height of the pandemic.
Adding the larger than normal one time impact on our profitability.
Our gene therapy manufacturing operations in Maryland also faced unforeseen challenges as we scale up the commercial volumes required in a new ERP system and successfully completed the three regulatory inspections.
Stepping back I believe a root cause of these challenges and increased costs at <unk>.
Two different coffee cliffs, we experienced a revenue, Greece and an unprecedented operational Khalifa.
Allow me to explain.
In the last year, while we have spoken of the colleague Clipper, we usually meant the significant decline in revenue as the world emerge from the worst of the pandemic, which occurred much faster than expected or forecasted.
Both covenanted debt is expected to translate into slightly more than 50% decline in our fiscal 2003 Cogs related revenues compared to fiscal 'twenty two when coffee related revenue was approximately $1 3 billion.
With the well over half of these have been tied to take or pay or related component sourcing agreements.
While we expect some combination of coffee than other mrna respiratory vaccines to remain a meaningful part of our revenue stream in the years to come we don't have enough information at this point to forecast the expected full year impact in fiscal 'twenty four although we are planning for a significant year on year reduction.
But this significant drop in <unk> revenues.
Tell the whole story.
As you know our people did an extraordinary job expanding our operations to meet the demands placed on Azure.
On us by the global pandemic response.
Between meeting to the unprecedented COVID-19 vaccine demand and implementing growth initiatives to capitalize on the stronger longer term growth potential in biologics.
We expanded very quickly since at the end of fiscal 19, including by Abbvie. The approximately 7000 more work at <unk>.
Roughly doubling our workforce.
And invest and go over $3 $5 billion across our network some of which was intended to help offset that the revenue gap, but there will be inevitably emerge once the coffee crises faded.
We know now that we enter fiscal 'twenty three overly optimistic about our current year growth.
Our personnel in key processes.
Simply did not keep pace with a dramatic up and down this week that goes by call Vitor and.
And not only some of the anticipated revenue offsets not materialized as quickly as expected, but it is through a much more complicated to exit the pandemic operationally at this impacted sites.
Most importantly, we have not been able to reduce the cost that we added to the company, including personal mosquito inventory as rapidly as needed.
This is Dr. Operational Calvert cliffs, I mentioned driven by the extraordinary unprecedented complexity involved in implementing operational changes required to execute the ducommun programs and then people to produce the non coffee programs that will offset that those revenues and fuel our future.
Growth.
I believe we have made solid progress.
Leasing of those revenues with the new sources that will ultimately produce a sustainable long term growth.
However, it is now clear that we underestimated the related operational challenges and that forecasting suffered as a result.
Now that we fully recognize the depth of the challenges we are addressing them in a rapid fall.
Just manner.
Let me transition to forecasting.
Whenever actuaries upfront results varied materially from our expectations and projections.
Our underlying assumptions prove a substantially inaccurate data it is time to reassess our forecasting to be eager and discipline.
This includes moderating our short term optimism by more thoroughly assessing and integrated integrating that the negative impact of the recent macro events that event and continue to have a material impact on our business.
These include the significant contraction in biotech funding, which is especially impactful for newer modalities.
At the same time, we are building the foundations of our demand planning process in our biologic segment.
We have also conducted a root cause analysis of our forecasting this to improve our understanding of the internal operational drivers that led us to such an accuracy issue.
In Bloomington, and Bras Seltzer, we're more effectively waiting at the temporary impact of productivity challenges and ninth unexpected cost, including those associated with the regulatory remediation that generated a diverse manufacturing <unk>.
In Bloomington.
We expect it to some large products the tech transfers to 12 offset that a little bit of current demand at the site.
<unk> answer turned out to be more complex and I'm, taking longer than anticipated, resulting in overly ambitious a forecast.
Most of these are those have now been overcome.
And we expect that these transfers to complete in the second half of this calendar year.
On the positive side some of these tech transfers that tech types of customers are now asking and I need to Bloomington for their fill and finish work.
Gene therapy has been our bright spot this year.
Including the rapid growth in the first half of the year as we scale the business.
But we experienced significant unforeseen operational challenges in the business in the third quarter.
Yeah.
These challenges have continued into the beginning of the fourth quarter as we increased the capacity to serve growing demand.
As we first communicated on April 14th.
One of the key issues here involve the replacing of dws prior ERP system.
Which was better suited for smaller clinical and development operations.
While the implementation of the new ERP was critical to support the fundamentally bigger commercial operations at BWI. The challenges we experienced at implementation delayed the ramp up of this additional capacity until early may.
Again, these challenges were temporary and will not affect any customer.
As we have previously build a sufficient bright stock to support that they may get the needs.
And we are now producing in normal fashion.
Our focus in our pharma and consumer Health segment has also been too optimistic.
This is a segment, where we expected a strong growth as we started the year modified our expectations too much more modest growth in November and February and now tracking to flat organic revenue growth for the full year.
The main headwinds here on more pronounced declines in some existing commercial high value pharmaceutical products.
Lead the launches of some promising new prescription products and lower consumer demand, particularly for <unk> and <unk> and other high end in nutritional supplements we.
We are confident that the segment will return to organic growth in the coming quarters, given the growth we see in our core development revenue.
Expected rebound of our top product for the segment that experienced the supply chain challenges in fiscal 'twenty three.
Continuing the strong demand that we see for outside this platform and the expected launches of 10 products recently approved by the FDA.
To recap we have reviewed that the procedure that with which we execute our precise of processes to determine our micro events impacted our ability to meet that forecast after delivering three years of exemplary performance.
We are bringing back more rigor and skepticism, but less known and previously unforeseen macro and internal operational drivers at the same time, we now recognize the need to reflect better increased level of complexity involved in this new phase of our business.
While it is difficult to assign a precise figures due to the impact of this operation on forecasting challenges, we attribute about the same in marketing to the of those the two items in our overall net revenue and EBITDA guidance adjustments.
Concurrently and in conjunction with the changes in our finance leadership, we have conducted an independent third party balance sheet review and the two largest sites in our biologic segment Bloomington and BWI.
Most importantly, these balance sheet review the affirmed its overall its overall soundness, including our contract asset balances.
In all we expect to record a few accounting adjustments at Bloomington one.
One example, we expect to increase our inventory reserve by roughly $55 million related to certain raw materials and component to achieve the safety stock to minimize pandemic related supply chain shortages.
We also expect it to correct that $26 million of cognition related to the fourth quarter of fiscal 2002.
Separately, given our lower growth expectations for our consumer health business. We also expect to report a goodwill impairment in that business in excess of $200 million.
Okay.
Currently assessing and addressing the effect of these adjustments on our previously issued financial statements, including those in our most recent 10-K and our 10-Q for the current fiscal year as well as their effects on our internal control over financial reporting and disclosure controls and procedures are contributing to our delay.
Finalizing our third quarter. Thank you.
When our assessment is complete we will fully explained to our investors. These of prior period changes and that effects, including the effects on our internal controls.
We very much appreciate the patience of our shareholders as we work to resolve these issues in a timely fashion.
Moving onto a review of our manufacturing operations, we have taken several corrective actions at the BWI and Bloomington, including both management and operational changes to address the root causes of the issues identified at each site.
The operational challenge changes include the more rigorous demand planning.
Deployment of additional <unk>.
Well to be sources to recover previously experienced productivity levels.
And on holistic cost review.
The future organizational structure to the new outlook on our demand.
We expect that these actions to bring us back progressively to typical profitability levels at these locations.
We have also made a number of important leadership changes were.
We announced on April 14th that we appointed Vicki Optum to serve as our interim Chief Financial Officer.
<unk> is an experienced finance executive.
In operational finance expert, who deeply understand Scotland NK success to lead our financial function through this interim period as we search for a permanent CFO .
We also made the changes in the finance organization other changes in the finance organization in the last month.
Clothing, changing to finance directors and to the sites with the greatest challenges.
On the operational side, we made several executive leadership changes in our biologics segment.
As just one example, we are pleased that three captisol, yes, a proven biologics operations leader with the vast industry experience, who join tap I think being generally will now lead our operations worldwide across the biologics segment.
In addition in early March we announced that the street of accretion on our 20 year industry expert in lean six Sigma and the return to confidence to recognize the Kaplan way.
The covenant ways, a companywide the system of continuous improvement lean manufacturing with the clear standouts to enable more predictable and efficient processes.
When I speak about <unk>. It also means effectively managing costs and cash to ensure we drive the company's expected profitability.
We have developed and other cost reduction plan intended to drive much more aligned to our historical levels.
With a goal to double our previous committed $75 million to $85 million of annualized run rate savings from restructuring activities.
In addition, we are limiting our capex to August essential investments.
We are also actively evaluating our current portfolio to ensure we have a suite of business that achieve a sustainable profitable and capital efficient growth that delivers superior shareholder value.
I want to reiterate my disappointment between having to deliver this news.
My team and I accept the responsibility for falling short of your expectations and ours.
We nonetheless remain committed to two covenants long term vision.
The secular trends in our overall business and operating environment remains fundamentally strong.
We opened 18 January excellent markets with the industry, leading services capabilities to meet the customer needs that.
We are proud of our regular dividend, including this year, where in the last six months, we underwent nine a successful FDA inspections, all the fuel which included observations and all of those can be readily addressed.
Among these successful inspections with <unk> inspections at our gene therapy sides in support of our significant product.
We also see strong current and future demand for our broad platform of services.
And while lower biotech funding is impacted to some near term demand for some of our offerings in the newer modalities put it away from commercialization those assets that are closer to commercial approval or tools that they have already been approved which is well over half of our revenue when combined.
Continued their ordering process as expected.
We have also invested hundreds of millions of dollars in assets that are getting ready to be deployed at <unk>.
David by the market demand.
This included the additional new suites in BWI that now expected to be completed in fiscal 'twenty four.
Two state of the art.
Sterile syringe line $1 91 in Bloomington, and our NIE capacity expansion of our <unk> softening.
We estimate that the Westwood each plan the level of utilization of these larger footprint, we will be able to generate the $6 $5 billion in annual revenue without the need for substantial new growth capital investments.
We will let you know as soon as we're ready to announce our full quarterly results and provides any sit necessity further details regarding the addition of two our prior financial statements.
I will now turn the call over to <unk> for a discussion for a discussion of our capital position and expected the fiscal 'twenty three results.
Thank you Alexandra.
Turning first to our capital position and our debt load as discussed on slide six which we now intend to reduce more aggressively remains well structured at the midst good flexibility.
Our nearest maturity is not until 2027.
On most rigorous debt covenant is the ratio of first lien debt over the last 12 months of adjusted EBITDA at six five times.
This ratio at December 31, 2022 was roughly one six times and is expected to increase for the next several quarters for diminishing again in the back half of fiscal 2004.
This covenant ratio is expected to remain well below the permitted level throughout this period.
Our top priority is to positive cash generation and allocation of capital, which will support our efforts back towards our net leverage target of 3.0 times include greater utilization of our asset base completion of essential in flight Capex projects that we believe will add will gen.
<unk> positive returns in the short term activities that will reduce our cost base and <unk>.
Contract negotiations to reduce our cash conversion cycle.
We expect to report that our contract assets as of March 31, 2023 to be roughly flat with that.
December 31 2022 balance.
I understand the level of contract assets has been a top investor concern so and one of my first actions as interim CFO I initiated an independent review of the balance sheet, including contract assets at two of our largest sites and our biologics segment.
<unk> and BWI.
The review reaffirmed the overall size of our balance sheet, including our biologics contract asset balances some of which are related to nearly completed products, including the bright stock Alessandra Alessandra mentioned earlier.
Also related to contract assets the revenue accounting treatment for complex products with long production cycles will continue to be recognized on a percentage of completion basis when contract terminology determines our work related to commercial activity.
Note in the third quarter. It was a change in contract terms to a large gene therapy program that drove a change in characterization from development to commercial activity. So the percentage of completion method, we have been using all along will not change.
We are looking at other contract terms that may partially modify our content for this product. This is one reason for the delay in finalizing our third quarter results.
Finally, we now expect our fiscal 'twenty, three capex to be approximately $550 million versus our previous estimate of approximately $500 million.
When taken into account the billions of dollars of capital investments, we have already made in the business in fiscal 2024, we expect to be able to reduce our capex to only the most critical projects lead into a notably lower spend.
Now, we turn to our revised financial outlook for fiscal 2023 as outlined on slide seven.
We now expect fiscal 'twenty three net revenue in a range of $4 to $5 billion.
Up to $4 $3 $5 billion, we now expect.
<unk> adjusted EBITDA in a range from $725 million up to $775 million.
We now expect adjusted net income in a range from $187 million.
Up to $228 million.
One driver of this change is that we now expect an increased tax rate of 27% to 29% for the full year compared to our previous expectation and the 24% to 25% range. This increase is a result of the lower outlook for earnings before taxes in certain tax detriment items unaffected by reduced pre tax Inc.
The rate is also affected by changes in our anticipated full year geographic mix versus prior forecast as a larger portion of our earnings or losses of <unk>.
<unk> to a rise in jurisdictions that do not provide the immediate benefits of such losses and related deductions resulted in a rate detriment.
We now expect.
We continue to expect our share count to be in the range of 181 to 183 million shares.
Now I will provide some color on the temporary nature of the challenges impacting our margin in the second half of fiscal 'twenty three.
First in BWI as we initially shared on April 14, we continue to expect to recover in the first half of fiscal 'twenty for the revenue we failed to achieve this year due to our operational challenges related to the recent ERP implementation.
Also as noted in the April 14th announcement, the lost productivity and our drug product business, particularly in prelim tenant Brussels was very significant but we now expect those sites to ramp up towards previously forecasted productivity level in the next few months as we execute on our backlog including multiple.
<unk> Tech transfer programs.
Sure.
We have started another enterprise wide restructuring program with a goal to double our previous commitment of $75 million to $85 million annualized cost savings.
This includes costs eliminated through the completion of remediation activities in both Bloomington and Brussels.
We expected the annualized impact of these activities to be roughly $100 million.
Yeah.
Let me.
Let me reiterate again and my personal regret regarding these update.
However, I would like to close our prepared remarks by reaffirming decreased key strengths underlying good catalysts future.
First.
All our issues are temporary.
And fixes to our operations and leadership are already underway.
Second we have learned many lessons that would increase our discipline and rigor going forward.
Third we have a strong pipeline aligns with our core I quoted you asset base. It mentioned the most exciting trends in our end markets capable of delivering up to $6 5 billion since revenue with substantially lower future capital investments.
Finally.
Over the last several months, we have continued to see a strong support from our customers as illustrated by some of the expanded partnership formation of the area in our prior calls.
As a result capital and we will continue to play a critical role in delivering some of the most consequential therapies being developed and meeting our commercialization.
This is a reset moment for covenant.
But what is unchanged that is selling postbank arthritis to delivery of global healthcare non.
Not just for vaccines, but also for the eight other products we make.
Patients around the world need covenant and.
We are not.
To let them down.
Operator, this concludes our prepared remarks, we.
<unk> open the call for questions.
Thank you.
At this time I would like to remind everyone in order to ask a question.
And then the number one on your telephone keypad, we will pause for just a moment to compile the Q&A roster.
Yeah.
And we will take our first question from Josh <unk> with Morgan Stanley . Your line is open.
Yeah.
Hey, guys good morning, and thanks for the time here.
Alessandro Ricky maybe just to kick things off you took the revenue guide by about $450 million EBITDA by about <unk> 10 at the midpoint.
Can you just provide some of the quantitative.
The bridge essentially there in terms of perhaps the madura not take or pay contract or the quality remediation cost overruns.
Or any sort of Rev rec issues related to startup does drug.
Hey, Jeff This is Rick I'll take that question affect fair question. So look the way that we think about this.
The dynamic of.
The EBITDA decline being more than the revenue decline is in it.
So a couple of categories, so first and foremost the delayed.
And missed revenues predominantly.
Drop through to the bottom line the cost of the labor remains the cost of the overhead remains the only cost that is really eliminated is the materials. So it's a high margin drop through on those aforementioned revenues that were delayed in mist to a future period.
We our forecast was overly optimistic we have the aggressive timing of new new business coming in.
High margin business coming in and our plans to reduce our cost base well.
Were delayed by.
The necessary corrective actions that were taken to address the regulatory actions in and with the the balance sheet adjustments that we mentioned in our prepared remarks, the inventory reserves.
No impact on revenue of course, but impacted EBITDA. So with the combination of those factors you get to the dynamic where the EBITDA reduction is is more than that of the revenue reduction. So hopefully that provides some color for you.
Got it that's helpful and one quick follow up on the on the debt Covenant piece Ricky so.
Is it fair to assume from your prepared remarks that you feel very confident that you won't trip up that six five times debt Covenant and one for you Alessandro Big picture I know you talked about the new the new sort of some expansions of the contracts with <unk> and Novo you're you've also obviously.
One more quick Madonna with J&J, and then <unk>, the new contract as well, but there is a fair question to be had here in terms of customers' worrying about management being distracted as you look to fix all of these issues across the portfolio. How are those how are those conversations going and give us a flavor for how.
You're sort of assuring those customers that gasoline will be there for them.
Despite all of the other noise.
T J I'll just address the first point of your question, which was around the debt covenant and the answer to that is yes, we feel very confident.
Hey, Nigel Hi, Alexandre here. Thanks for the question a very good one.
Look overall as I said in my remarks that the customers remain very very supportive of the covenant story.
Our supply situations remain that remain very healthy.
Clearly when we enter some periods in which we are preparing for some change.
We have a number of contingency plans.
For those for those changes and so we are prepared to face potential challenges without without the risk of impacting our customers. So I personally spend a significant amount of my time.
Speaking with those customers providing them.
The color of those challenges.
Some of them have been very very close to what happened during the pandemic.
The surprised or shocked by what these that what is happening in terms of how difficult sometimes.
To some of these operations from a period of.
High growth back to to normal award so.
I would characterize those conversations as very supportive the very understanding and the pro fees <unk> expanded the relationship that we are we are we continue at the site.
Got it thanks, guys I appreciate the time.
Okay.
And we will take our next question from Jacob Johnson with Stephens. Your line is open.
Hey, Thanks, good morning.
I know, it's probably too early to comment on FY 'twenty four but honestly, it's a focus for investors and you guys talked a little bit about the outlook for leveraging in the back but as we think about the 725 plus million of EBITDA in FY2023 the comments you made about leverage, peaking and in FY 'twenty four.
The middle of the year.
And then also the potential for significant approvals. There's a few puts and takes here. So can you just talk about what the key swing factors or whether or not FY 'twenty four EBITDA could be higher or lower next year like is this a trough number in FY2023.
Yes sure.
Look.
Thanks, Thanks for the question.
Look I believe that we.
It's clearly early to speak about the fiscal 'twenty four.
In may, but I understand the nature and the relevance of the question Youre asking Luca will you look at some of the prepared remarks, we have provided today. We have tried to give some color around that the temporary nature of of the cost. The challenge is when I look at the overall picture.
And notwithstanding the fact that we.
We entered into this fiscal year with the more ambitious expectations for topline growth above our non coffee the revenues this year, even with the current the revised guidance, we will still be in the mid single digits growth given that you're little situation of the market is eases somewhat aligned.
I believe that that will have an necessary at demand the problem here.
We have a costa.
<unk> related also to execution challenges.
We have provided.
<unk>.
I believe you enough color to pass out both of these costs are temporary nature right now to think about them going forward into the next fiscal year, and so being able to cut them out to fund the kind of the current outlook.
Okay. That's helpful. Thanks, Alessandra and then maybe.
Thank you and thanks for the question.
I appreciate the $6 5 billion kind of revenue potential Academy.
Can you just talk about some of the kind of near term cost dynamics and I think guidance implies.
Depressed EBITDA margin in the back half of this year.
As we think about the long term I think once upon a time you guys were targeting 30% EBITDA margin.
Let's say you get to $6 5 billion of revenue when do you think is a reasonable EBITDA.
The margin profile on that level of revenue.
So look I believe the answer is a pretty much of connecting the dots all United.
You mentioned that so what we are sharing is that we already have an asset base that has the potential of $6 $5 billion, which means that in many ways. Our operating leverage at the moment is pretty low.
So there is a lot of potential by driving a higher level of utilization into the assets that we have created and we have a buildup.
Clearly when we made the seasons of these investments.
Biotech funding environment was different than it is today some of the the environment, we were leading into what a little bit different but we believe that those trends.
In the long term are still valid.
That operating leverage that we.
We were expecting.
We continue to expect that to come back and so we do see a significant potential of expanding our margin going forward as surely getting more aligned to the flight plan that that we would be Scott zynga only a few months ago.
Okay got it thanks for taking questions.
Okay.
We'll take our next question from Julia Quinn with Jpmorgan. Your line is open.
Hi, good morning, Thanks for taking our question here.
So first of all regarding ongoing customer conversations.
I heard you reiterate.
These customer relationships.
Roger Please people here.
Just curious how do you have.
Any changes in terms of pricing contracting terms.
Or to kind of stabilize or maintain these customer relationships and are those any potential changes are reflected in your updated guidance.
So look clearly.
The pricing <unk> is a very difficult out there to keep.
But the price environment, given the diverse portfolio that we have.
Running in Chile in the last year has been a key point of our negotiation with the customers in terms of.
When you're leaving us such a high inflationary environment.
You need to get the.
The two customers with some some pricing to offset that inflationary.
The environment in general I would say that that has been the not substantial changes to our contract terms.
The reality is.
As we look into the future and across the different modalities the pricing power that we have continues to be very different.
In general I believe that in the segments, where we're seeing unhealthy level of demand we have mentioned multiple times the prefilled syringes.
In inkjet and I'll fill and finish shifting in services, we continue to see some healthy level of pricing. There. So so I would say that in general I don't see the environment changing dramatically from a from a pricing standpoint.
Got it very helpful.
Hum.
Organizational changes that you mentioned earlier.
Could you give us more color on kind of a no deal.
Uh huh.
Any additional personnel departure.
And whether or not they're in function that could impact that.
Impact your production capacity.
Give us a sense of you know where are you.
Your current production capacity.
Compared to normal levels and how quickly do you think you can refill those positions and get back to normal productivity.
Yes sure sure so let's start the question loci.
It always fastest for you to consult our website, which is shows that some of the.
All the changes that they've been at least at the executive level, but clearly.
There were several of those what I can tell you is that in these periods of where the job is to regain the past performance Isa.
Very helpful to be able to topping the known the leaders that have been with the company has already been in these positions already and can be redeployed to restyle. What was what was there before so I was very pleased to have the opportunity to have those leaders available to make the change you see in a very fast fashion going.
The first solutions that will define known entities with a proven track record, but so I'm very confident that the changes we've done to <unk>.
Whether we get decent Alba, the capital <unk>, and Schrader, which I mentioned in my remarks.
We have now the tema debt that is needed there too to really correct of course is established.
The performance of the company I would also mention that I have a lot of trust in Ricky.
He knows that the operational finance of the company like nobody else.
And our segmented markets very well so he is he's going to be very helpful. In these interim periods in rebuilding some of the forecasting processes that especially in the newer parts of our business are not dead.
As a strongest day out in our legacy assets.
You got to have your your question around productivity levels.
The work as I said is already underway.
We're addressing these with the speed and pace.
The way I would cut out that ICD is it will take.
A lot of work in some time, but we are already making progress and I can already see.
Notwithstanding that we're not in the position of the Deepness of 70 quarterly phasing, but I can share that they're already seeing Q4 progress Isa versus Q3.
Got it that's helpful. And then last one from me you mentioned opportunities for portfolio.
In your prepared remarks.
Are there any preliminary thoughts you can share with us at this point and will you be pursuing those that portfolio strategy efforts simultaneously as you all work on the other issue. That's all for me. Thank you.
So the first the first part of the answer these debt.
This is not surprising I've already signaled that I do believe that any point in time, we need to conduct the assessment of our portfolio to understand what that that I'd assets of four foot covenant and if.
If at any point in time, we have today.
The order of what other asset so I do believe that as we have the bill to the company in the last few years and are right now to more than 50 sites, we have some significant opportunities.
Probably EMA in getting.
And for some of the assets are thinking about the better ownership, but keep in the face of those assets are in.
So it's an ongoing evaluation that we do.
We do continuously clearly I cannot deny that the current.
Updates that we had on the outlook.
Surely have accelerated some of those evaluations. So we are the simple answer to the second part of your question is that yes, we are doing these.
We also look at improving the productivity levels at our more critical sites.
Okay.
Yeah.
We will take our next question from Dave Windley with Jefferies. Your line is open.
Hi, Thanks, a couple.
I heard Ricky talk about $100 million annualized number that I think was targeted at.
At costs and the additional restructuring. So my first question is how much of the original 75 to 85 has already been harvested and is reflected in the new EBITDA.
Guidance that youre, giving today.
Versus how much of what I guess would now be like $160 million target would still be targeted to take out beyond that guidance.
And beyond that guidance.
Dave So I would I.
I would say when we announced in May.
The cost reduction changes in November 2022.
We remain on track to deliver approximately half of that in the second half of our fiscal <unk>.
The second.
Cost reduction exercise that we're embarking on now.
We would expect to see the majority of that come through in our fiscal 2024.
Okay helpful. Thank you.
And then secondly, a little broader question so.
Kind of in invoking the contract asset review I appreciate the comments there.
And the guidance and the magnitude of change so.
Correct me, if I'm wrong, but it seems like you're saying that you've reviewed contract assets and it seems like you're particularly pointing at Baltimore in Bloomington, the big sites.
I would say that.
Revenue recognition related to percentage of completion accounting through the December balance sheet date, Youre, saying you are comfortable with.
That that certainly give us some assurance around.
Previous Rev Rec.
It doesn't say that the.
$510 million of EBITDA that you're taking out is essentially all second half EBITDA, but this was this is all kind of from a chronological standpoint fiscal second half of the year impact is is there.
Is there anything about that then I should think about differently.
As I think about that.
The run rate that is implied by the second half EBITDA X X. These cuts.
Youre thinking about that correctly.
But when you think about the second half also consider what we alluded to in terms of the one time costs that impacted the second half run rate the full 500.
Is related to the second half is not related to the first half, but as I said.
A number of one time.
Non recurring items in that.
Second half okay understood.
Understood.
And then I guess bigger picture question.
<unk>.
The $6 5 billion the productivity expectations I guess, what in this review I understand you know some of this is still in flight.
Yeah.
I guess Alessandra, what I'm really interested in is.
What gives you the confidence.
Given that last answer what gives you the confidence that you can get up to or back to target margin slash productivity levels.
In light of some factors that if we exclude the one time items factors that make the margin in the second half look really really bad help me help me understand your confidence in the long term productivity, yes sure sure. So look we need to go to the root causes.
To get to the confidence right. The way you look at the <unk> and this is primarily related to my commentary around the operational coffee cliff.
So youre talking about <unk>.
<unk> the workforce, a little less Catherine but this was very much concentrated in very few locations. Okay. So that will of course.
Needed and necessity for the mission we went on.
But on winding that these.
Cost in DCF count in the middle of.
Implementing.
Remediation actions before for Capex related to foreign fees is not the easiest of the task and I'm not searching for excuses here Im just saying that these are highly highly complex then surely we have underestimated the complexity, which truly at the plants to realign the cost structure to the reality of the product mix in the port.
Folio, but we had to make some decisions that tradeoff in delaying of those doors.
We don't implement the FTC stem 70 day, and we don't do them or to the extent we do it every day. This was a necessity to be done.
And we were mindful of that we have to do it early naphtha before a potential approval to have time to recover if something was not growing quite as expected.
So there would a decision be made that there are things that are there.
Very very special to this fiscal year, many firsts and many first timers as I said, we learned a lot, but they also recognize that some of those elements.
It will reverse as we go into the next few quarters.
Seth I already see.
The.
That makes it the recent performance better than the more the.
The most performance that the other element that you need to think of we have field.
A significant number of assets in the new modalities, which have a very low level of absorption of utilization at this point in time now as I said before.
Our expectation and forecast was to feel of those offsets.
In the cell therapy space.
Much faster than the world really happen and that's a combination of many items. Some are environmentally radiata I believe some are assessed reflection that we need to do on our go to market strategy.
But the overall appeal of those areas remain so as we and to be honest with you. These all these assets are at the mining at the moment the heavily <unk>.
Margin dilutive to the to the organization and the latest solid element looking at the portfolio consider issuance is also a consideration at all and will start to offset that at the moment, the nonstrategic and deal with Eva and Dws. It's also that we need to look at that so I hope I gave you all the elements data to get to the same.
Level of confidence however that to the fundamental pricing of the business remains the same the fundamental demand profile remains the same the fundamental technologies that we use are the same and so all when you consider all this together, we will get back to the margin of where where what needs to be.
That's very helpful. I appreciate it I wanted to ask one last quick one and that is on the contract asset Ricky coming back to that can you I understand that's I believe that's applied to your development stage work.
And.
Could you comment then on.
Like are in the aging of that from an <unk> standpoint, So I know you cant bill for it yet, but like how long or how long dated or some of those contract assets how far back do they date. Thank you.
Okay.
Yes, David look it's something that we obviously will look at we have SaaS.
But at this stage, it's not something that.
Concerns in terms of the aging profile of those contract outfit.
Contract asset balances.
There is an engine that greater than one year it would be deemed on the balance sheet, our long term contract asset.
But just to clarify one point the contract assets not just for development as I've mentioned in the prepared remarks lodging.
A large in therapy program, which.
<unk> is now being treated as is.
It is a con.
Contract assets as well from a development standpoint, so maybe I will add some other.
Information, which would be we have already shared services like because if you think of what is already been.
Made the know and clearly as we got into these new modalities day, but we didn't realize how longer the production might be also due to some of the media to testing that is required. So there are several step of the process about between steps that are very long testing times, which you're essentially it'll cannot progress.
The cross on things such as testing is completed in that time as a niche of the in quarter. So it is not measured in months. So of course, we know much better now with the process ended up to be on some of these new modalities.
We are actively discussing also with our customers around how we can look at these from a contractual standpoint, it's alloy does having too much working capital.
Tied to we deal with these assets as we go forward.
In the in the in the future. So it's very much not lost on us.
Creating and inefficiencies from a working capital standpoint, then we need to find the ways to address it but but the depth that is a big contributor to these contract asset and is a big contributor also of the <unk> because you have a several quarters worth of production at any point in time that is waiting to be.
Finalized with the last steps of the process by.
By design.
Okay.
Dave just to make the point also the balance sheet review that we conducted.
Did confirm the overall samna solve our contract assets, which included the aging profile of those balances.
Understood very much appreciate the answers thank you.
Yeah.
We will take our next question from Paul <unk> with Keybanc. Your line is open.
Yes, thanks for taking the time. So in effect are you going to have to re price in the future.
Film therapy projects do you think that.
And also the method by which you're doing the percentage of completion.
Recognition is that have to be adjusted both how you price that in.
The.
Method of.
Recognition.
So let's vessel.
If I understand well your question was around the pricing growth cell therapy user.
Or maybe I would say look you're asking both the cell and gene therapy. So I'm going to give you a little bit more broader answer I don't believe that gene therapy that is any pricing.
So you can either get changes into the future I do believe that from cell therapies. We are still finding the right process to produce these therapies.
Inefficient way is not lost on the industry that we need to make sure that the visa therapies are made available to a wider group of <unk>.
Patients because they have a significant even thought the so we are really working with our customers and some of our key partners from a component standpoint to try to find the solution. So to have more efficient processes that doesn't necessarily mean, then only the price, but also the cost of those processes to be to be addressed so yes, I believe that instead therapies over.
The next few years, so you're going to see changes in those regards but I believe it's a good thing because they will allow for patient access at these these therapies and as a result, we will have a more volumes for us to manufacture.
With regards to both of your.
Second question. Okay can you specify the question I wanted to understand exactly what you what you what you're asking.
The the milestones needed to achieve revenue recognition have you learned in this process of those need to be modified.
I don't necessarily believe that that is a matter of milestone so I believe that the.
What we learned is that.
Sometimes.
Probably the invoicing.
<unk> along the process could.
Could be different and and so that to get all of it will be faster. These body three acre from contract assets. We are at for me or to cash in the bank. So I believe this is the learnings.
And I believe what we are trying to address those learnings attacking them from different angles. So one and I believe that we have opportunities to make the process a much leaner much faster.
Especially when it comes to the testing element Davita and the other part I believe that that we cannot we cannot we cannot read these also together with our customers.
A lot of vendors, referring to the balance sheet aspect.
The working capital aspect no change from a P&L perspective from a revenue recognition.
And then the last question is regarding Bloomington in Brussels.
Did you expand beyond of.
Of course, you did the work to comply with a 483, but did you expand facilities in those locations as well going above and beyond the 483 needs and they are running now is that correct.
Look.
I would tell you that.
Spending to the footprint, especially in Bloomington, Yes, as we mentioned many times that we had I think additional lines being installed there is the question isn't around but as we go over and beyond the what.
Not necessarily in the <unk>. They look at every every regularly spectrum needs a checkpoint that an opportunity to reflect the wolfcamp b improved and the covenant is always Ed.
A very holistic approach to these situations.
So yes, we go over and beyond because we are here for the long haul and whenever we have the opportunity we need to make sure that we address everything at the same time in a holistic fashion no matter, what the FDA needs into shop there.
Yeah.
Okay. Thank you.
Yeah.
And we will take our next question from Derik de Bruin with Bank of America. Your line is open.
Hi, good morning.
Just some clarification on some things so.
How much revenue from fiscal 'twenty, three is getting pushed into fiscal 'twenty four right and specifically I'm curious about the gene therapy drug that's going commercial.
What was that push and pull.
We've heard some fairly big numbers out there on what that contribution can be the company I would appreciate any sort of clarity on how to think about that in the margin for the group.
Look.
But this is Alessandro I appreciate the question I had really understand the reason why you are asking.
I would tell you though that it.
It's premature for us to make any comment.
For Visco said before is not that the time is aiding the question I understand the reasons are we going to try to keep that these quantification in due course as soon as possible.
But it is a complicated equation because that is the demand, but also the additional scale up of capacity you want to do to catch up on that demand how fast you could do it to where he is going to happen in the first half of his kept it before the second half of fiscal third before.
I'm, just not warranted not not that I don't want to answer that is just that we need to somewhat work to make it that qualification and I can promise that this so that we can have that available if we get a shifting so with the with you guys.
Right.
Clarify that you've got product that you've already made.
That can supply.
Patients that are expected to be dosed with that drug for the next 12 months absolutely absolutely we had.
But if you feel like a part of the reason why we have the contract asset that we have is because part of that go up with US a piece of what we call the price stock.
<unk> is a stock that can be converted in final product with only a few remaining steps of the process, So and the way to wants to sign the final.
Information is available of market labels and so forth. So yes, we were.
Well aware that that is ramp up that might be it might have been.
More complex than others, because you said new processes, new modalities and there is ERP applications and so forth. So we were very.
Very much mindful of building to stock ahead of the time, so that we could.
Periods of adjustments without impacting supply cannot definitely.
Very very clearly because this is important to me is important to the patients out there that is noticed the supply of any of these products.
Have you recognized revenue on that product.
To some percentage of completion according to our policies.
Okay.
Let me try something else.
And how much do you think of your revenue mix is.
Tied to the biotech issues.
<unk>.
Just because I mean, one would argue that's not going to come back next year and.
I'm also just curious you know you had a 6% to 10% guide for the PCH business longer term that seems to be.
It would be off the table now given some of the asset write downs and things. There can you just were talking about everything about that.
So sure look.
The biotech funding is there is clearly a situation that these are still very volatile I would say volatility there continues to be fairly high I believe we were the first one the speaking openly that there would have been a challenge in November .
It continues.
Continues to be a little bit of a challenge, especially for early stage programs and especially in new modalities I want to stress that in the new modalities because of the nature of them, but we are we have.
Our high level of exposure to the biotech the biotech industry and as such to the biotech funding. So I believe that that the first half with the second half of this calendar year, we will continue to be a period of volatility.
And we need to continue to observe but what is happening there.
In terms of understanding at the.
The time for recovery.
There is there are some elements, though that are more in our control in that regard so we choose.
The late stage programs, which are less affected by that because theyre, so closer to potential commercialization of which have not really affected by the funding because you're going to you're going to progress those and I believe that on those ones that we have.
More visibility and we are more optimistic.
With regards of the PTA segment.
When you look at what was in the in the script that the web T elements that really affected our outlook. This year and made the dis business, which was expected to be.
A contributor of growth that would be more flattish story. One was that we had some delayed approvals that's the decent Sweden right. Sometimes that you have an ear so periods, where you have the approval so together in Peter's where they just get delayed.
The first half of this year was disappointing because many of these approvals when in fact, the data as such the launcher will lead us out there in the last few months, we received 10.
Sometimes you don't control those events.
The good news is that then now they've happened and so as we look into the fiscal 'twenty. Four this is gonna be launches that are actually going to happen.
I believe this year, we suffered from higher than expected erosion of some of our portfolio in the prescription business.
Erosion, there was expected to open up in a little bit faster I believe is now bottoming yet to the levels to for these products there will be sustained going forward.
We have resolved the some supply meaning.
Meaning at all Mojito challenges of 401, the key product we have in that segment. So during the summer we expect to be back on the supply of those one with regard of the consumer I got to tell you a little bit. The same response that I gave before the biotech I believe is still a volatile environment.
We're still monitoring it.
We continue to convert the portfolio to larger bigger more diverse customers.
But.
Thats, an environment, where we continue to observe in the next six months cycles I hope with diesel these color helps you.
It does thank you and just one final one just to be clear you don't do you need any restatements do you think beyond fiscal 'twenty two.
Basically just if you go back and you look at the pre Covid numbers, you've restarted annual capacity are those.
Are those numbers say from what you've recorded.
Yeah.
I would say.
<unk> continued to assessment.
Address the effect of these adjustments that we discussed previously.
Previously issued financial statement financial statements when the assessment is complete.
We'll be back and fully explain to our investors. These prior period changes in FX.
On our financial statements.
Thank you.
Yeah.
And we will take our next question from Lukas <unk> with.
Barclays. Your line is open.
Great. Thanks for the questions.
So before the operational challenges you guys were doing about $300 million plus or minus in EBITDA per quarter.
And so like outside of the next few quarters and you've clearly been below those that level, but when do you guys expect to or when can we think about reasonably think about when that will get back to those types of levels.
Mike.
Back half of 'twenty four.
Okay.
<unk> going to be like a 25 issue.
Look I believe that.
As I said the visa.
Quite some time and some work.
I have confidence that we're going to get back there. It also depends on the on the top line and so there are many variables attached to ETA.
And of course as you know we are a picky consequential events on the horizon in the next few weeks. So I believe it's hard to make a prediction, but I believe that if you assume a calendar 'twenty for you.
Faster from where we are supposed to be.
Okay great.
And then I guess on <unk>.
On the approval can you.
For the gene therapy.
You guys are scaling up to I think it was like 16 or 18 suites.
Can you update us on what that manufacturing capacity.
Do you guys need to build out additional suites, because it's clearly taking.
More.
Materials and inventory to make to make the drug then when was the earlier than anticipated.
Okay. So we said that the BWI BWI facility give us either with the with a lot of capacity and we.
We believe that we are creating.
Capacity for our covenant.
Kevin needs about this facility can continue to serve.
The demand in gene therapy for years to come after the expansions that we have done. So there is a lot of capacity available. There we feel very comfortable is a premium facility.
He is a commercially approved this is very recently two most successful inspections.
Is it still a jewel in the crown of covenant notwithstanding some of the short term challenges, we discussed with our gift implementation very.
Very very pleased with our strategic and very optimistic about the future.
Okay, and then lastly here on the <unk>.
Sticking with the percentage of completion.
How do you.
We plan to do that through actually the after the drug is approved assuming it does get approved.
How does it work.
Yes so.
We concluded on the canton.
With regards to that product it will be continued on a percentage of completion base.
Basis, but as we shared during our prepared remarks with such a complex agreement we are looking at of a.
Contract terms that could prospectively modify our accounting for that product going forward.
Yeah, right I mean, because it gets approved its commercialized that's no longer development right. So it would have to be recognized in batch commercialization.
No no.
The point is it will be we will continue to recognize it if it is approved and it is a commercial product on a percentage of completion basis.
Got you alright. Thanks.
We will take our next question from Jack Meehan with Nephron Research. Your line is open.
Thank you good morning.
So my question is simple can you grow EBITDA in 2024 based on the transitory impacts you've talked about can you just confirm 2023, what you've laid out is this going to be the trough.
So look clearly this question requires the sum.
Get all Youll make at these answers are based on assumptions. So based on some assumptions of visa I would say that.
Credible expectation.
Grant and some key assumption is also regarding to some expected approvals in the next few months.
Okay.
And then I believe I heard.
You mentioned, the Covid forecast down 50% year over year. So it sounds like you maintained it at over $600 million for the fiscal year could you confirm that and what's embedded for the second half of 'twenty.
It's about right, yeah, we pretty much expect that to be the number.
Maybe a little bit different.
Facing but yes, yes, yes, we can.
No change to our private previous.
The months around that number a little more than $600 million.
Great and one final what was the $26 million impact in the fourth quarter of 'twenty, two you'd called out.
Yeah.
As a result of the balance sheet review.
But we are still.
Ongoing one of the reasons why we are.
Late in Q3.
Financial statements.
Is it did lead the review did lead to some accounting adjustments and one that we shared today was to correct a $26 million Rev.
Revenue error related to a.
Fiscal 2022.
Overall, I'm very pleased with the pace that that the overall quality.
Of the review that we're doing to make sure that we don't leave any stone unturned.
Thank you.
Okay.
And we will take our next question from Matt <unk> with William Blair. Your line is open.
Alright, thanks for taking our questions just wanted to follow up on a earlier question and the point from the deck around net leverage, peaking in the middle of fiscal 2024.
I know you said, it's a little too early to give a guide on next year, but can you just confirm that net leverage peaking in the middle of fiscal 'twenty 'twenty 4 million adjusted EBITDA in the first half of next year will be down year over year.
Again, we have not completed a full assessment of fiscal 'twenty for myself I'm getting up to speed here all financial matters at Kaplan Meier.
My focus has been around.
Q3 financial reporting commitments and at this stage, we don't have a.
Our fully built out FY 'twenty four.
The.
Yeah, I would say look at.
That being said Dell ratio is always calculated on an LTM basis right. So are these also leaving is not necessarily only the next couple of quarters is always look at the fourth quarter. This effect. So that there is an encouraging factor there.
Yeah.
Okay got it maybe just a couple of quick ones on <unk>. There was a lot of focus last week during their AD com on the ratio of empty capsid can.
Can you just discuss what's going on there why you changed the manufacturing process to one that has higher empty capsid and did not add steps to adjustment since you and then whether or not there could be some CMC issues moving forward as a result, even though the FDA has already completed its inspection at your at BWI facilities.
Switzerland look.
That is that is North America <unk> changed the process, sometimes where you develop a drug there are processes that are suitable for the early clinical stage.
And that they are not necessarily.
Suitable for larger clinical production.
Commercial production, so and so it is sometimes use different technologies with this process.
I don't believe that there was a.
And you commented on the visa is going in and around the nature of what we do benches Gabe is not the same old if that field scale.
It is an industrial what we use here.
In industry standard process.
That thesis with these type of therapy used in many other.
Programs.
And and I believe the data continued to be pretty sound also with regards of the use of these a process that's been said.
We are in.
The industry, where we always look at opportunities to flip the renouncing processes, but as it stands today. This is an industry standard is more suitable for the large commercial volumes and.
The data supporting the use of this process.
Okay got it. Thank you maybe just one final one from me answering that you mentioned already having product for initial dosing of patients and understand that SRP 901, as a big opportunity moving forward, but how should we think about the potential revenue in fiscal 2024, given <unk> said during that time that it only expects to treat about 100 patients in the first six months post launch.
Does this mean that we could actually see a step down in revenue from this program in fiscal 2024, especially considering thermo can be up and running by then thank you.
So look on.
On the basis that the product is approved.
As our well received.
Accelerated approval I want to be more specific.
Surely I do not expect that there would be a.
A deduction.
Okay perfect. Thank you for taking my questions.
We will take our next question from Jon <unk> with UBS. Your line is open.
Hi, Thanks for taking the question I just wanted to dig in a little bit deeper on some of these emerging biotech that you mentioned earlier I guess some of your peers have provided what percentage of revenue is there exposure would you be willing to provide that and maybe even X raptor and gene therapy, what does that look like for your customer base.
And then <unk>.
Mentioned that there were no customer cancellations, but assuming that some of these companies have no capital do you think that maybe these assumptions here a little bit more too optimistic.
Could be cancellations here moving into next year I mean.
Of course whenever that make a commentary on how you can comment at all on the sizeable notable cancellations youre not business because we are in the clinical world and do you think those outages that are all the time cancellations just because of the nature of the business that some of the most of these programs do fail. They go through the clinic. So I just want to caveat that.
That that you know I wasn't referring to large notable commercial supply agreements that with potentially being cancelled then can have a material impact on the company with regards of your comment that our the optimism I believe we'd be pretty humble and opening here and see that yes would be an optimistic I don't believe necessarily.
On the rate of cancellations I believe we've been optimistic around the amount of assets of which would have been entered into clinical progressing through the clinic.
In the last call it nine months.
And the pace at which this was happening now is very very different from what it was.
In 2021, and 2022, I would say <unk> to meet the 2020 to meet the 2022 has been a sharp correction.
We've seen it from auto position observational standpoint.
But the science is still there and the potential.
The unmet need there for patients who are still there.
And the efficacy and safety profile of these field. There. So these are all elements that will bring these back at some point.
So yes, we were optimistic yes, now we have learned and we have a more realistic.
Outlook, but yes, we continue to be bullish about the long term prospects of these modalities.
Right and then I guess just on the Brussels facility.
Previously.
Principally it didn't provide the timeline there I just want to confirm the.
The timelines on when you think that these productivity issues would be resolved and then just from a high level can you remind us on the overview there what percentage of that facility is dedicated to de Novo and we go there.
So on the last question I cannot give you that information made states such as simply that we are not authorized to share without the.
Our customers. So I can tell you that for cross sell so we are in now the facility is now finally fully up and running after compete itself.
Of challenges and and especially where you would start to form of these long periods.
It's complicated to reach it.
Efficiency levels that experienced before I would say until that honestly the steel a while we have but we are now at the full absorption.
Working progress I still believe that the industrial stuff.
We can are we going to have to do more work and will require some more time.
To be honest with you but.
Good news there is that we have all the demand that we want because we have to recall that on a low backlog. So the absorption and utilization isn't going to be a problem, but it's just recovering.
The amount of operating a consistency that we had before and we're making very good progress in that direction, but it is something that just doesn't happen overnight, where you experience the challenges that we've experienced.
Thanks for taking the questions.
Yeah.
And we will take our next question from Sean Dodge with RBC capital markets. Your line is open.
Yes, Thanks, Alex.
I was wondering you said.
The Bloomington Tech transfers the couple that you have won there and working on launch.
More complex and taking longer than expected did I hear correctly. Those are done now and up and running and then as we think about how meaningful those or could you I don't know.
Maybe compare the size of those relative to the Covid work in Bloomington that you're you're working to backfill.
Sure. That's a great question so first of all.
I believe that that they can't got challenges in <unk> that we experienced.
The code up experience delay to the final steps of the validation of these program had been overcome now so nice is ease.
Completing the last steps in waiting for the regulatory timing that is required that would be to get ourselves into position to to put commercial production. So.
As we said in our remarks, so we expect this to be a cycling the current body of 'twenty three.
The impact in terms of fees.
These are meaningful products so.
I can tell you that at this point in time up it gets concern is to have enough capacity more than demand that we're trying to make an effort of cleaning up of installing additional capacity. There. So that we can support.
What we envision to be.
Very high demand products.
Because the end market is a very strong and at the moment there is not fully satisfied.
It's difficult to make a parallel to the carbon the times because it is a very different product.
I can tell you from a profitability standpoint, we are aligned in terms of the margin.
Clearly you need to understand that there is no product in the world that there will ever be producing 1 billion doses.
In 18 months that is significantly pizza themselves in terms of what we've done in Bloomington. So I believe that was a little bit of a unique unique situation but.
Net of debt, which we have now already washed out of our numbers.
It is a video of the portfolio that we have down there.
Okay, Great and then you pointed out that you will continue to win new business, including an expansion with with Novo.
When was that expansion sign and maybe any more color you can provide there.
Kind of involving you working with them on more products or is this expanding what you're doing with them beyond the Brooklyn facilities.
Yes, yes, sure sure locates as clearly as we bring the new assets online that we gave and disasters or the $90 million youre going to expect that we've said that repeatedly in the ultra some of our competitors are giving same information right. So when you look at these.
Clearly, where you have these new assets coming online. The first thank you do you offer debit to your existing partners with which you have a very healthy established and a fruitful discussion and many time more times than not and decent in the recent.
In the recent months those customers have picked up on the on the author tool to go and some other sites and to go to some other capacity <unk> capacity. So.
I believe that that's very very exciting for us. The fact that the customers continue to give us confidence in continuing to want to serve from Mazda.
Is probably the best testing that can happen to us.
Okay, all right great. Thank you Dan.
Okay.
And we will take our final question from Justin Bowers with Deutsche Bank. Your line is open.
Thank you and good morning, just have two sort of broader questions and then I'll follow up offline with the rest but.
With respect to gene therapy, and I am just piecing together.
A few comments.
From the call but.
You did say that you have.
Additional suites coming online.
We ended the year. So I'm curious if that's referring to BWI, two and as you move through the air.
End of this calendar year.
And then the second part of that.
You had some comments around seven quarters of production waiting to be released.
So.
Is that reflected.
Sort of in the contract asset.
On the balance sheet.
And I'll pause there.
Philosophically.
Okay.
Yes.
Yeah.
Okay.
Okay.
Mr Matsui.
Yes.
Yeah.
Sorry.
Ed.
Oh I apologize this is the operator.
Okay.
Our speaker line is still connected however, I'm not hearing any audio from them.
Please standby.
Okay.
Okay.
And ladies and gentlemen, we appreciate your patience.
<unk> continue to standby, while we reconnect our speakers we will resume momentarily.
Okay.
Yes.
Yes.
Okay.
Okay.
Okay.
Okay.
And ladies and gentlemen, we appreciate your patience. Please continue to standby, while we reconnect our speakers.
We will resume momentarily.
Okay.
Okay.
Okay.
And ladies and gentlemen, thank you for your patience, we do have our speakers reconnected.
Okay.
Sorry, everyone. We had an outage here at our location. So we are reconnecting from mobile so.
Can you. Please ask again the last question.
Yeah sure so.
Two questions one on I guess, a gene therapy, and then one just related to the guide down.
With respect to Keith you talked about bringing new capacity online I'm just curious.
The timing is up to the end of this year and is that related to BWI and all it suites.
Talk about before part two of that is you also said that you have sort of seven quarters.
Production.
I believe wait.
Waiting to be released.
And the contract assets I don't want to I don't want to paraphrase, but I just want to clarify that.
That is what you said so that's related to the gene therapy, and then I'll come back with the second one on the guide.
Let me, let me address the last one I didn't see several quarters. They said a few minutes I just will say that is not contracted the process. Glenn is not three months is easy.
Is it more is longer than that that depends on a few things by you need to think about the deposit plant from start to finish somewhere.
And in the several months, a typo, but type of timeframe and we are working actively to reduce debt with regards of the suites. Yet is BWI. The ones. We were referring to you don't have to think about these as a binary event that they told US that you have all the suites of these suites have the ability to come online that broke that you believe.
In the in the DC capitals, according to sell because of the policy to be allowed that to happen. So you have a tool than another to another to embed over the next few months that we're going to bingo line that these additional capacity.
Understand and that makes sense.
Was that one of the inspections.
We're one of the inspections related to those suites as well and then.
Just the other parts of that in terms of the contract terms since youre still doing it on percentage of completion as it sounds like the amendment that Youre looking for is maybe around invoicing is that is that fair.
So the first part of the question.
Look the inspection never bite suite that you expected the hold for <unk>.
Regularly standpoint, BWI MPW, who it belongs to the <unk>. So you need to look at these the way you guys expected inspection or would you say that once again that chemicals so that.
The answer to your first part of the question. So very very pleased that those inspections were successful because the gain is an impact to that.
These are the inspection of related to that but the day about day about an impact on Eurosport edp so very.
Very pleased with that outcome.
And with regards of the of the Tam to local.
A little bit of a clarification here.
Brighi was referring to some other terms of the contract with the gaps of our revenue recognition mechanisms there beyond the percentage of completion I do believe that we have an opportunity to and we are already making progress you see in terms of setting the different milestone supporting voice <unk> going to have absolute going forward that we're going to continue to work against the visa. These.
Yes.
Okay, and then just quickly on the.
On the change in the guide it sounded like the 500 bid 400 was related to forecasting and then the other 100 was related to sort of.
The one timers I just wanted to clarify that and then.
Of the one timers you guys did spike out sort of $55 million in inventory markdown is that one of those one timers and as that.
Running through the P&L with the new guidance. Thank you.
Yes.
So I would say Dallas Undrawn.
I would say that.
Youre right about the 50.
<unk> 55 in terms of the one.
One of the one timers.
But after that one time.
Estimated to be roughly.
Equally 50 50 between the forecasting challenges Alessandro referred to and the operational and productivity challenges being the second.
<unk> for the quarter NOI guidance, yes.
That would add to that.
When you think about one timer Ricky the first the one time or do you feel like most of them are financial accounting standpoint, but even also in the execution challenges that are issues that we deem are temporary in nature, which we are addressing that we've done we don't believe that big.
It will affect the long term the business before months of Roma profitability standpoint.
Okay I appreciate I appreciate the time.
Okay.
Alright.
So.
Yes.
Holidays ladies.
Ladies and gentlemen that concludes the question and answer portion of today's call I will now turn the call back to Mr. Alessandro Maselli for closing remark.
Thank you. Thank you everyone for taking the time to join our call and your continued support of Covenant.
Ladies and gentlemen, this concludes today's conference call. We thank you for your participation you may now disconnect.
We thank you for your participation you may now disconnect.
Yeah.